The partnership between the Food and Drug Administration and the Medicines and Healthcare products Regulatory Agency aims to streamline technology access and reduce regulatory duplication.
The Medicines and Healthcare products Regulatory Agency (MHRA) and the US Food and Drug Administration (FDA) are increasing collaboration on medical device regulation to support faster access to new technologies for patients in both countries.
The announcement builds on a broader US-UK pharmaceutical partnership that removes tariffs on UK medicines exports and encourages companies to launch new treatments. This regulatory collaboration is designed to reduce duplication for innovators while maintaining safety standards.
Aligning Approval Processes
The MHRA and FDA will work to improve and align regulations for medical devices, including the exploration of future mutual recognition mechanisms. These mechanisms would allow the agencies to recognize parts of individual approval processes, streamlining the path for manufacturers to bring new medical technologies to market.
“Closer working between the UK and the US means that future innovative medical technologies—better diagnostics, smarter devices, life-changing treatments—can reach NHS patients sooner, without compromising on the safety standards we rightly expect,” says Dr Zubir Ahmed, health innovation and safety minister, in a release. “This is. the correct next step. We’ve already acted to secure improved access to life-changing medicines for NHS patients. Now we’re working to make sure the devices and technologies that go alongside them follow the same path.”
While the agencies will collaborate on technical work, both regulators will remain independent to ensure safety standards are upheld. Future arrangements must continue to meet statutory requirements for safety, quality, and effectiveness.
Impact on Life Sciences and Innovation
The partnership is part of an effort to ensure the UK remains a leader in life sciences research and development. By creating more predictable processes, the agencies aim to help companies navigate regulatory requirements more effectively.
“By strengthening our working relationship with the FDA, we are allowing cutting-edge medical technologies to reach patients faster and more efficiently than ever before,” says Lawrence Tallon, MHRA chief executive, in a release. “This is exactly the kind of partnership that enables the UK to stay at the forefront of global life sciences.”
Industry leaders noted that the alignment would be particularly beneficial for small and medium-sized enterprises. Julian David, techUK chief executive, stated that internationally connected regulation shows momentum toward reducing duplication.
“Closer cooperation between the MHRA and FDA is a positive step towards reducing regulatory duplication and accelerating patient access to HealthTech that saves and enhances lives,” says Peter Ellingworth, chief executive of the Association of British HealthTech Industries, in a release. “For UK businesses, greater alignment between two of the world’s leading regulators will provide more predictable pathways and support faster routes to market, while maintaining the highest standards of safety and performance.”
Technical assessments between the two agencies will continue over the coming months to identify further opportunities for alignment and mutual recognition.
ID 219160314 © Andrey Popov | Dreamstime.com
